PL3902541T3 - Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds - Google Patents
Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compoundsInfo
- Publication number
- PL3902541T3 PL3902541T3 PL21720509.5T PL21720509T PL3902541T3 PL 3902541 T3 PL3902541 T3 PL 3902541T3 PL 21720509 T PL21720509 T PL 21720509T PL 3902541 T3 PL3902541 T3 PL 3902541T3
- Authority
- PL
- Poland
- Prior art keywords
- deuterated
- therapeutic compositions
- partially
- dimethyltryptamine compounds
- dimethyltryptamine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Addiction (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/890,664 US11771681B2 (en) | 2019-06-03 | 2020-06-02 | Therapeutic compounds |
| PCT/EP2020/065244 WO2020245133A1 (en) | 2019-06-03 | 2020-06-02 | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| GB2008303.6A GB2585978B (en) | 2019-06-03 | 2020-06-02 | Therapeutic compositions |
| GBGB2018955.1A GB202018955D0 (en) | 2020-12-01 | 2020-12-01 | Compositions and compounds for bioanalysis |
| US17/108,938 US20220169606A1 (en) | 2020-12-01 | 2020-12-01 | Compositions and compounds for bioanalysis |
| GBGB2018950.2A GB202018950D0 (en) | 2020-12-01 | 2020-12-01 | Parenteral formulation |
| US17/108,679 US20220168274A1 (en) | 2020-12-01 | 2020-12-01 | Parenteral Formulation |
| US17/208,583 US11773062B2 (en) | 2021-03-22 | 2021-03-22 | Deuterated compounds |
| GB2103981.3A GB2605144A (en) | 2021-03-22 | 2021-03-22 | Deuterated compounds |
| PCT/EP2021/060750 WO2021116503A2 (en) | 2020-06-02 | 2021-04-23 | Deuterated compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3902541T3 true PL3902541T3 (en) | 2022-11-14 |
Family
ID=84083617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21720509.5T PL3902541T3 (en) | 2020-06-02 | 2021-04-23 | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
Country Status (10)
| Country | Link |
|---|---|
| JP (1) | JP7288154B2 (en) |
| KR (1) | KR102589605B1 (en) |
| CN (1) | CN116056763B (en) |
| AU (1) | AU2021204158B2 (en) |
| CA (1) | CA3179161C (en) |
| ES (1) | ES2928395T3 (en) |
| IL (1) | IL298541B2 (en) |
| MX (1) | MX2022014900A (en) |
| NZ (1) | NZ794833A (en) |
| PL (1) | PL3902541T3 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2666149A1 (en) * | 2006-10-19 | 2008-04-24 | Auspex Pharmaceuticals, Inc. | Substituted indoles |
| WO2019081764A1 (en) * | 2017-10-26 | 2019-05-02 | Consejo Superior De Investigaciones Científicas (Csic) | Combination product for the treatment of neurological and/or psychiatric disorders |
| GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| MX2022005399A (en) * | 2019-11-07 | 2022-07-05 | Small Pharma Ltd | Compounds. |
-
2021
- 2021-04-23 PL PL21720509.5T patent/PL3902541T3/en unknown
- 2021-04-23 ES ES21720509T patent/ES2928395T3/en active Active
- 2021-04-23 CA CA3179161A patent/CA3179161C/en active Active
- 2021-04-23 JP JP2022574099A patent/JP7288154B2/en active Active
- 2021-04-23 AU AU2021204158A patent/AU2021204158B2/en active Active
- 2021-04-23 KR KR1020227045704A patent/KR102589605B1/en active IP Right Grant
- 2021-04-23 IL IL298541A patent/IL298541B2/en unknown
- 2021-04-23 NZ NZ794833A patent/NZ794833A/en unknown
- 2021-04-23 MX MX2022014900A patent/MX2022014900A/en unknown
- 2021-04-23 CN CN202180046463.XA patent/CN116056763B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021204158B2 (en) | 2023-03-02 |
| CN116056763A (en) | 2023-05-02 |
| KR20230007547A (en) | 2023-01-12 |
| AU2021204158A1 (en) | 2023-01-05 |
| KR102589605B1 (en) | 2023-10-13 |
| IL298541A (en) | 2023-01-01 |
| NZ794833A (en) | 2023-03-31 |
| JP2023520256A (en) | 2023-05-16 |
| IL298541B1 (en) | 2024-04-01 |
| ES2928395T3 (en) | 2022-11-17 |
| CA3179161C (en) | 2023-10-31 |
| JP7288154B2 (en) | 2023-06-06 |
| CN116056763B (en) | 2024-03-05 |
| CA3179161A1 (en) | 2021-06-17 |
| MX2022014900A (en) | 2023-03-27 |
| IL298541B2 (en) | 2024-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288617A (en) | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds | |
| EP4031529C0 (en) | Deuterated or partially deuterated n,n-dimethyltryptamine compounds | |
| MX2020001404A (en) | Dihydrooxadiazinones. | |
| GB202102895D0 (en) | Novel compounds, compositions and therapeutic uses thereof | |
| IL273286A (en) | Solubilization of chlorhexidine base, antiseptic or disinfectant compositions | |
| GB201915828D0 (en) | Compounds, compositions and therapeutic uses thereof | |
| PL3902541T3 (en) | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds | |
| IL310176A (en) | Deuterated compounds | |
| IL311050A (en) | Deuterated empathogens | |
| GB2603446B (en) | Disinfectant composition | |
| EP4230210A4 (en) | Stable pharmaceutical composition | |
| GB202107169D0 (en) | Therapeutic compositions | |
| GB202010639D0 (en) | Therapeutic compositions | |
| GB202103981D0 (en) | Deuterated compounds | |
| PL3945821T3 (en) | Disinfectant compositions | |
| GB202012797D0 (en) | Disinfectant composition | |
| GB202115200D0 (en) | Retentive formulation | |
| GB201915831D0 (en) | Compounds, compositions and therapeutic uses thereof | |
| GB201915829D0 (en) | Compounds, compositions and therapeutic uses thereof | |
| GB202311283D0 (en) | Therapeutic compositions | |
| GB202207263D0 (en) | Therapeutic compositions | |
| GB202315915D0 (en) | Disinfectant formulation | |
| GB202315914D0 (en) | Disinfectant formulation | |
| GB202015687D0 (en) | Therapeutic composition | |
| GB202102142D0 (en) | Stable fungicidal compositions |